Avantor, Inc. 2021 First-Quarter Form 10-Q Summary
Business context and reporting period
Avantor is a global manufacturer and distributor serving biopharmaceutical, healthcare, education and government, and advanced technologies and applied materials customers. The filing covers the unaudited three months ended March 31, 2021, compared with the three months ended March 31, 2020.
Key financial metrics
| Metric | Q1 2021 | Q1 2020 | Change |
|---|---|---|---|
| Net sales | $1,785.6 million | $1,519.0 million | 17.5% increase |
| Gross profit | $612.8 million | $501.9 million | $110.9 million increase |
| Gross margin | 34.3% | 33.0% | 130 basis-point expansion |
| Operating income | $266.3 million | $158.4 million | $107.9 million increase |
| Net income | $164.0 million | $47.0 million | $117.0 million increase |
| Net income available to common stockholders | $147.9 million | $30.9 million | $117.0 million increase |
| Diluted EPS | $0.25 | $0.05 | $0.20 increase |
| Adjusted EBITDA | $363.1 million | $262.8 million | 38.2% increase |
| Adjusted EBITDA margin | 20.3% | 17.3% | 300 basis-point expansion |
| Operating cash flow | $126.9 million | $253.1 million | $126.2 million decrease |
| Free cash flow | $111.8 million | $240.5 million | $128.7 million decrease |
Reported sales growth included 13.5% organic growth and a $59.6 million favorable foreign-currency impact. Segment sales were $1,035.2 million in the Americas, $650.4 million in Europe, and $100.0 million in AMEA.
Financial position, debt and liquidity
- Cash and cash equivalents were $172.5 million at March 31, 2021, compared with $286.6 million at December 31, 2020. Including restricted cash, total cash was $175.1 million.
- Total debt was $4,632.8 million net of deferred financing costs, compared with $4,893.9 million at year-end 2020. Gross debt declined to $4,702.0 million from $4,972.2 million.
- The company made $202.1 million of term-loan prepayments during the quarter and recorded a $5.2 million non-cash loss on extinguishment of debt.
- Unused credit-facility availability was $803.5 million, producing reported total liquidity of $976.0 million when combined with cash.
- Required term-loan payments over the next twelve months were $22.7 million. The company stated that it was in compliance with its debt covenants.
- Accounts receivable increased to $1,201.5 million and inventory increased to $777.7 million from $1,113.3 million and $739.6 million, respectively, at December 31, 2020.
Material changes versus the prior comparable period
- Revenue growth was driven by strong demand in biopharmaceutical, healthcare, and education and government markets, including COVID-19-related PPE, diagnostic testing, vaccine-production, and biopharmaceutical offerings.
- Proprietary materials and consumables grew strongly, supporting a 150-basis-point favorable product-mix effect on gross margin. Lower vendor rebates and inventory manufacturing variances offset 20 basis points.
- Interest expense declined by $43.0 million because of debt repricings, refinancings, and lower debt balances.
- Operating cash flow and free cash flow declined substantially because of increased working-capital requirements, incentive compensation payments, interest-payment timing, and higher capital expenditures.
- Foreign-currency translation produced a $37.8 million other comprehensive loss in Q1 2021, compared with a $67.4 million loss in Q1 2020.
- The effective tax rate declined to 22.4% from 27.4%, primarily because of geographic earnings mix and a larger discrete tax benefit from stock-based compensation exercises.
Outlook, commentary, risks and unusual items
Management described the first quarter as benefiting from continued recovery as economies reopened, as well as ongoing COVID-19-related demand. The filing does not provide a clear quantitative full-year revenue or earnings guidance range.
On April 12, 2021, after quarter-end, Avantor entered into an agreement to acquire privately held Ritter GmbH and affiliates for an upfront equity purchase price of approximately €890.0 million in cash, subject to final adjustments and potential milestone payments. Closing was expected in 2021 and remained subject to customary conditions and regulatory approvals.
- COVID-19 continues to create both demand opportunities and risks to operations, results, cash flows, and financial condition.
- Key disclosed risks include supply-chain and raw-material availability, dependence on limited suppliers, competition, customer and distributor relationships, acquisitions and integration, foreign exchange, interest rates, cybersecurity, regulatory compliance, product liability, environmental obligations, and leverage.
- Known environmental liabilities included a $3.5 million accrued obligation for groundwater remediation in Phillipsburg, New Jersey, and a $3.2 million liability for remediation and monitoring in Gliwice, Poland.
- The company stated that no outstanding litigation was expected to result in a material loss. Separately, it expected to settle certain EPA reporting matters for less than $1 million.
- The company corrected immaterial classification errors in prior-period product-line sales and cash-flow disclosures; reported consolidated results and operating cash flow were not affected.
Important facts for investors to verify
- Whether COVID-19-related demand, including vaccine, testing, PPE, and diagnostic sales, persists or normalizes.
- The sustainability of the 34.3% gross margin and 20.3% Adjusted EBITDA margin after cost controls and favorable product mix change.
- Working-capital trends and the decline in operating cash flow and free cash flow.
- Debt reduction progress, future interest costs, required maturities, covenant headroom, and exposure to variable interest rates.
- Funding, regulatory approval, integration execution, and milestone obligations related to the proposed Ritter acquisition.
- Potential costs and timing associated with environmental, product-liability, regulatory, and other contingencies.
- The impact of foreign exchange, given the company’s global operations and material non-U.S. cash balances.